Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains

References

• Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462–478
   PubMed Web of Science ®Google Scholar
• Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569–574
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685–702
   PubMed Web of Science ®Google Scholar
• Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45: 321–346
   PubMed Web of Science ®Google Scholar
• Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115–125
   PubMed Web of Science ®Google Scholar
• St-Germain G, Laverdière M, Pelletier R, Bourgault A-M, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949–953
   PubMed Web of Science ®Google Scholar
• Lodder J. The Yeasts. A Taxonomic Study1st ed. American Elsevier Publishing Company, New York 1970
   Google Scholar
• Barnett JA, Payne RW, Yarrow D. A Guide to Identifying and Classifying Yeasts. Cambridge University Press, Cambridge 1979
   Google Scholar
• McGinnis M. Laboratory Handbook of Medical Mycology. Academic Press Inc, New York 1980
   Google Scholar
• Haley LD, Callaway CS. Laboratory Methods in Medical Mycology4th ed. US Department of Health, Education and Welfare. Centre for Diseases Control, Atlanta, GA 1978
   Google Scholar
• Drouhet E, Dupont B, Improvisi L, Viviani MA, Tortorano AM. Disk agar diffusion and microplate automatized techniques for in vitro evaluation of antifungal agents on yeasts and sporulated pathogenic fungi. In: Iwatak K, Vanden, Bossche H In vitro and in vivo evaluation of antifungal agents. Elsevier science Publishers, Amsterdam 1986; 31–49.
   Google Scholar
• Reviákina V, Mendoza M, Panizo M. Estandarización y aplicación práctica del método de disco difusión para Candida albicans frente a fluconazol. Antibiót Infecc 2004; 12: 31–44
   Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A2. 2nd edn. NCCLS. Wayne, PA, 2002.
   Google Scholar
• Pfaller MA, Boyken I, Messer SA, et al. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 2005; 43: 5208–5213
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicentric comparison of EUCAST and CLSI M27-A2 broth microdilution method for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884–3889
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Karlsson A, Bolmstrom A. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 1998; 36: 2586–2589
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol ; 39 1997; 2001: 3254–3259
   Google Scholar
• Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole againts 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program. J Clin Microbiol ; 41 2001; 2003: 1440–1446
   Google Scholar
• Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from SENTRY antimicrobial Surveillance program. J Clin Microbiol ; 44 2003; 2006: 1782–1787
   Google Scholar
• Capoor MR, Nair D, Deb M, et al. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital. Jpn J Infect Dis 2005; 58: 344–348
   PubMed Web of Science ®Google Scholar
• Mujica MT, Finquelievich JL, Jewtuchowicz V, Iovannitti CA. Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clínicas. Período -2001. Rev Arg Microbiol ; 36 1999; 2004: 107–112
   Google Scholar
• Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from to 2000 in a population-based active surveillance program. J Clin Microbiol ; 42 1998; 2004: 1519–1527
   Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, and the SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40: 852–856.
   Google Scholar
• Rodero L, Davel G, Soria M, Vivot W, Córdoba S, Canteros CE, Saporiti A, y participantes del grupo EMIFN. Estudio multicéntrico de fungemias por levaduras en la República Argentina. Rev Arg Microbiol 2005; 37: 189–195
   PubMedGoogle Scholar
• Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164–1170
   PubMed Web of Science ®Google Scholar
• Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis 2000; 19: 319–324
   Google Scholar
• Rowen JL, Tate JM. Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis 1998; 17: 1007–1011
   Google Scholar
• Waggoner-Fountain LA, Walker MW, Hollis RJ, et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 1996; 22: 803–808
   PubMed Web of Science ®Google Scholar
• Weems JJ, Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14: 756–766
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6.970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723–1727
   PubMed Web of Science ®Google Scholar
• Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073–1080
   PubMed Web of Science ®Google Scholar
• Skrodeniene E, Dambrauskiene A, Vitkauskiene A. Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 2006; 42: 294–299
   PubMedGoogle Scholar